# MRD Chat Evaluation Report

## Summary

| Metric | Value |
|--------|-------|
| Date | 2026-02-11 |
| Endpoint | `https://physician-system-production.up.railway.app/api/mrd-chat` |
| Questions | 5 |
| Average Score | **7/10** |
| Pass Rate | **1/5 (20%)** |
| Pass Threshold | 8/10 |
| Errors | 0 |

## CDS Safe Harbor Compliance

| Criterion | Pass Rate | Description |
|-----------|-----------|-------------|
| Criterion 3 (Non-directive) | **5/5** | No forbidden language, no single-option funneling |
| Criterion 4 (Transparency) | **0/5** | Citations, structure, evidence levels |

### CDS Violations (9 total)

- **Q1** [C4] `citation_missing`: DECISION: Based on the available sources, it is unclear whether adjuvant therapy should be intensifi
- **Q2** [C4] `evidence_levels`: No evidence level characterization found (e.g., randomized, phase III, Category 2A)
- **Q3** [C4] `citation_missing`: - Evidence: Standard guidelines would not recommend adjuvant therapy for this patient profile (pT4aN
- **Q3** [C4] `citation_missing`: - Evidence: Both NCCN and ESMO acknowledge the investigational nature of MRD-guided treatment decisi
- **Q4** [C4] `citation_missing`: - Evidence: Recent validation studies have demonstrated that circulating tumor DNA assays can detect
- **Q4** [C4] `citation_missing`: Based on the available sources, it is unclear whether extended therapy carries cumulative toxicity r
- **Q5** [C4] `citation_missing`: - Evidence: Recent prospective data suggest substantial lead time over imaging-based detection, with
- **Q5** [C4] `citation_missing`: Serial monitoring can help distinguish true molecular relapse from assay noise, and recent data sugg
- **Q5** [C4] `citation_missing`: Based on the available sources, it is unclear whether there is an established threshold for tumor fr

## Category Breakdown

| Category | Average | Count |
|----------|---------|-------|
| clinical_scenario | 7/10 | 5 |

## Dimension Breakdown

| Dimension | Average | Max |
|-----------|---------|-----|
| accuracy | 1 | 2 |
| completeness | 1.2 | 2 |
| evidence quality | 1 | 2 |
| automation bias mitigation | 1 | 1 |
| criterion3 nondirective | 2 | 2 |
| criterion4 transparency | 0.8 | 1 |

## Failures (4)

### Q2 (clinical_scenario, standard) — 6/10

> Stage III rectal cancer patient, completed 3 months of FOLFOX post-surgery. Signatera just came back MRD-negative. Is there evidence to support stopping chemo early rather than completing the planned ...

**LLM Assessment:** LLM score 4/7 (extracted from malformed JSON)
**CDS violations:** 1

| Dimension | Score |
|-----------|-------|
| Criterion 3 (auto) | 2/2 |
| Criterion 4 (auto) | 0/1 |
| Accuracy (LLM) | 1/2 |
| Completeness (LLM) | 1/2 |
| Evidence Quality (LLM) | 1/2 |
| Automation Bias (LLM) | 1/1 |

### Q3 (clinical_scenario, challenging) — 7/10

> 64-year-old, stage II colon cancer, pT4aN0, MSS, no high-risk features besides T4a. Post-surgery Signatera is MRD-positive. Standard guidelines wouldn't call for adjuvant chemo here. What does the MRD...

**LLM Assessment:** LLM score 4/7 (extracted from malformed JSON)
**CDS violations:** 2

| Dimension | Score |
|-----------|-------|
| Criterion 3 (auto) | 2/2 |
| Criterion 4 (auto) | 1/1 |
| Accuracy (LLM) | 1/2 |
| Completeness (LLM) | 1/2 |
| Evidence Quality (LLM) | 1/2 |
| Automation Bias (LLM) | 1/1 |

### Q4 (clinical_scenario, challenging) — 7/10

> TNBC patient, had neoadjuvant AC-T, partial response, then surgery with residual disease. Post-op Signatera is MRD-positive. She already got capecitabine per CREATE-X. Any ctDNA-guided options beyond ...

**LLM Assessment:** LLM score 4/7 (extracted from malformed JSON)
**CDS violations:** 2

| Dimension | Score |
|-----------|-------|
| Criterion 3 (auto) | 2/2 |
| Criterion 4 (auto) | 1/1 |
| Accuracy (LLM) | 1/2 |
| Completeness (LLM) | 1/2 |
| Evidence Quality (LLM) | 1/2 |
| Automation Bias (LLM) | 1/1 |

### Q5 (clinical_scenario, challenging) — 7/10

> HR+/HER2- breast cancer, stage IIA, had lumpectomy + adjuvant ET. Now 18 months out, surveillance Signatera just turned positive. No imaging findings yet. What does the literature say about lead time ...

**LLM Assessment:** LLM score 4/7 (extracted from malformed JSON)
**CDS violations:** 3

| Dimension | Score |
|-----------|-------|
| Criterion 3 (auto) | 2/2 |
| Criterion 4 (auto) | 1/1 |
| Accuracy (LLM) | 1/2 |
| Completeness (LLM) | 1/2 |
| Evidence Quality (LLM) | 1/2 |
| Automation Bias (LLM) | 1/1 |

## Full Results

<details>
<summary>Click to expand all 5 results</summary>

| Q | Category | Score | Pass | Missing Terms | CDS |
|---|----------|-------|------|---------------|-----|
| 1 | clinical_scenario | 8/10 | PASS | - | 1 violations |
| 2 | clinical_scenario | 6/10 | FAIL | - | 1 violations |
| 3 | clinical_scenario | 7/10 | FAIL | - | 2 violations |
| 4 | clinical_scenario | 7/10 | FAIL | - | 2 violations |
| 5 | clinical_scenario | 7/10 | FAIL | - | 3 violations |

</details>
